The current stock price of CLPT is 13.605 USD. In the past month the price decreased by -13.16%. In the past year, price decreased by -25.82%.
ChartMill assigns a fundamental rating of 3 / 10 to CLPT. While CLPT seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CLPT reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -21.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.34% | ||
| ROE | -145.77% | ||
| Debt/Equity | 1.84 |
8 analysts have analysed CLPT and the average price target is 28.56 USD. This implies a price increase of 109.92% is expected in the next year compared to the current price of 13.605.
For the next year, analysts expect an EPS growth of -20.94% and a revenue growth 14.96% for CLPT
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.63 | 195.24B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.45 | 175.531B | ||
| SYK | STRYKER CORP | 24.01 | 138.077B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.19 | 110.114B | ||
| IDXX | IDEXX LABORATORIES INC | 43.43 | 51.625B | ||
| BDX | BECTON DICKINSON AND CO | 11.5 | 48.913B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.49 | 44.712B | ||
| RMD | RESMED INC | 21.1 | 38.469B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.72 | 36.104B | ||
| DXCM | DEXCOM INC | 27.05 | 26.584B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The company provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. The company also offers IRRAflow active fluid-exchange system.
CLEARPOINT NEURO INC
120 S. Sierra Avenue, Suite 100
Solana Beach CALIFORNIA 92618 US
CEO: Joseph M. Burnett
Employees: 115
Phone: 19499006833
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The company provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. The company also offers IRRAflow active fluid-exchange system.
The current stock price of CLPT is 13.605 USD. The price increased by 0.11% in the last trading session.
CLPT does not pay a dividend.
CLPT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
CLPT stock is listed on the Nasdaq exchange.
8 analysts have analysed CLPT and the average price target is 28.56 USD. This implies a price increase of 109.92% is expected in the next year compared to the current price of 13.605.
CLEARPOINT NEURO INC (CLPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).